FOXO4-DRI Dosage, and Why the Sequence Stops
Every other step in this process has an answer. This one does not, and pretending otherwise would mean inventing it.
FOXO4-DRI dosage is the step in this sequence with no answer. No human being has received this peptide in a registered clinical trial, so there is no established dose, no tolerability ceiling and no measurement of how it behaves in a person. This page gives the published animal figures and the vial arithmetic, and no human protocol.
Where the order actually gets placed
Ascension Peptides, FOXO4-DRI
US-based and third-party tested. Enter the code on the payment step and the vial halves before you confirm.
The two published certificates cover different batches and disagree on net content: Kovera Labs assayed batch 55-05260628 at 11.41 mg, MZ Biolabs assayed lot 55-01260229 at 8.30 mg, both against a 10 mg label. Endotoxin and sterility screens appear on the Kovera batch only. The vendor spells the product FOX04 with a zero, including in the link. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Two batch certificates per lot
- Shipping free over $250
- Out the door same day if you order before 2pm CST
Everything here is research material for laboratory use, not for human consumption. FOXO4-DRI is not an approved medicine in any market and has never been tested in a human trial. Affiliate links, so we may earn a commission at no cost to you. Prices last checked September 2, 2026.
Why there is nothing to give you
Every other stage of buying and handling this compound has a defined answer. This one does not, and the reason is structural rather than a gap in reporting.
A dose is the output of a process: phase 1 trials establishing how a compound is absorbed, distributed, metabolised and cleared in humans and what dose begins to cause unacceptable effects, then phase 2 finding where benefit appears, then a regulator reviewing all of it. The number on a label is what comes out the end.
None of that has happened here. There is no measured human half-life, no bioavailability figure, no clearance route, no maximum tolerated dose and no adverse-event dataset. A dosing chart in that situation is a piece of writing, not a summary of evidence.
What the published animal work used
For completeness, because the question deserves a real answer rather than a refusal.
In the 2017 study, mice received FOXO4-DRI at 5 mg/kg, three times on alternating days, on days 1, 3 and 5. Administration was intravenous in the chemotoxicity experiments and intraperitoneal in the ageing cohorts. Doxorubicin, used to drive cells into senescence in that model, was given separately at 10 mg/kg in mice.
Two features of that schedule are consistently misreported. It was intermittent, three doses across five days rather than an ongoing course. And the routes used are laboratory routes in laboratory animals; intraperitoneal injection is not a route used in human medicine outside narrow clinical circumstances.
Why the mouse figure does not convert
The obvious move is to multiply 5 mg/kg by a body weight and apply a scaling factor. Interspecies allometric scaling is a real method, but it estimates a starting point for further study rather than producing a usable dose, and it needs inputs this compound does not have.
Scaling assumes you know how a compound is handled by the target species. For FOXO4-DRI in humans, nothing is known. A D-retro-inverso peptide is specifically engineered to resist protease degradation, which is likely to change persistence relative to an ordinary peptide, and by how much in a person is unstudied.
There is also the question of what you would be aiming at. The mouse experiments measured senescent-cell clearance in specific tissues under specific stressors, and the relationship between that and any human outcome has never been established.
The step before it, which does have an answer
Reconstitution arithmetic is simple: mass divided by volume gives concentration. The difficulty is the mass.
Kovera Labs certified batch 55-05260628 at 99.411% purity with net content of 11.41 mg. MZ Biolabs analysed lot 55-01260229 at 99.97% purity with net content of 8.30 mg. Both vials were labelled 10 mg.
| Starting mass | In 1 mL | In 2 mL | In 3 mL | | --- | --- | --- | --- | | 10 mg, from the label | 10.00 mg/mL | 5.00 mg/mL | 3.33 mg/mL | | 11.41 mg, Kovera batch | 11.41 mg/mL | 5.71 mg/mL | 3.80 mg/mL | | 8.30 mg, MZ Biolabs lot | 8.30 mg/mL | 4.15 mg/mL | 2.77 mg/mL |
Anyone holding the January batch and calculating from the label carries a concentration error of roughly 17%, and every volume drawn inherits it. Use the net content from the certificate matching your lot. The peptide calculator does the conversion correctly once the input is right.
Handling, which is not dosing
The lyophilised powder is the stable form, which is why it ships dry. Kept cool, dark and sealed it is comparatively durable, and there is no benefit to reconstituting in advance.
Bacteriostatic water rather than sterile water permits repeated withdrawals, because it contains a preservative. Direct the solvent against the vial wall and swirl rather than shake; agitation denatures peptides and visible foaming is evidence of it. Reconstituted material belongs refrigerated, protected from light, and used within a much shorter window than the dry powder allowed.
One further reason for caution: senolysis is not uniformly beneficial. A 2023 study found clearing senescent cells could worsen pulmonary hypertension, so the absence of a human dose sits alongside an absence of human safety data.